Physician profile
Javier Fleites
NPI 1699420059
$2,575.78
in general payments reported to CMS, 2019-2025
30 companies · $806 in 2025
The $806 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $372 · 2023: $933 · 2024: $465 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,169 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,168.69 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $241.08 | 2023-2025 | Gemtesa, Orgovyx |
| Blue Earth Diagnostics | $212.10 | 2022-2025 | Posluma |
| Ferring Pharmaceuticals INC. | $171.32 | 2025 | Adstiladrin |
| Tolmar, INC. | $160.95 | 2023-2025 | Eligard |
| Myriad Genetic Laboratories, INC. | $159.28 | 2023-2024 | Prolaris |
| Procept Biorobotics Corporation | $147.41 | 2024 | Aquabeam System |
| Janssen Biotech, INC. | $136.06 | 2023-2025 | Erleada |
| Pfizer INC. | $124.57 | 2022-2024 | |
| Boston Scientific Corporation | $124.04 | 2022-2025 | Axonics, Spaceoar System, Spaceoar Vue System - 10ml |
| Abbvie INC. | $116.38 | 2023-2025 | |
| Coloplast Corp | $109.10 | 2022-2023 | Speedicath |
| Endo Pharmaceuticals INC. | $99.00 | 2022-2023 | Xiaflex, Aveed, Edex |
| Janssen Scientific Affairs, LLC | $93.95 | 2025 | Balversa, Akeega, Erleada |
| Tolmar Pharmaceuticals, INC. | $85.39 | 2022 | |
| Progenics Pharmaceuticals, INC. | $82.23 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $64.09 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $57.17 | 2022-2023 | Myrbetriq |
| Axonics, INC. | $52.30 | 2022-2023 | Axonics |
| Teleflex LLC | $52.08 | 2022-2025 | Barrigel |
| Halozyme INC | $44.74 | 2023 | |
| Convatec INC. | $39.43 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $35.06 | 2025 | Imfinzi |
| Urogen Pharma, INC. | $26.80 | 2025 | |
| Olympus America INC. | $25.19 | 2025 | Itind System |
| Endo USA, INC. | $23.47 | 2025 | Aveed, Xiaflex |
| Merck Sharp & Dohme LLC | $21.62 | 2023 | Lynparza |
| Bioprotect Medical, INC. | $21.41 | 2025 | Bioprotect Balloon Implant System |
| Dendreon Pharmaceuticals LLC | $19.84 | 2022 | |
| Urovant Sciences INC | $15.60 | 2022 | |
| Dentsply Ih Ab | $14.12 | 2023 | Lofric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Fleites listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.